Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Henriksen

Showing results (31-40 of 154) with videos related to

Pageof 16
Sort By:
Scientific Reports|April 9, 2025
A fragment of Calpain-1 cleaved α-Synuclein quantified in serum is upregulated in patients with Parkinson's diseaseSigne Holm Nielsen, Cecilie Møller Hausgaard, Meryem Benmarce, et al.
European Journal of Clinical Pharmacology|October 9, 2009
Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacyMorten A Karsdal, Inger Byrjalsen, Kim Henriksen, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 18, 2007
Are nonresorbing osteoclasts sources of bone anabolic activity?Morten A Karsdal, Thomas J Martin, Jens Bollerslev, et al.
BMC Endocrine Disorders|January 8, 2021
The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profileAnna Thorsø Larsen, Sofie Gydesen, Nina Sonne, et al.
European Journal of Pharmacology|June 2, 2015
KBP-042 improves bodyweight and glucose homeostasis with indices of increased insulin sensitivity irrespective of route of administrationSara T Hjuler, Kim V Andreassen, Sofie Gydesen, et al.
Menopause (New York, N.Y.)|January 5, 2021
Treatment with a dual amylin and calcitonin receptor agonist improves metabolic health in an old, obese, and ovariectomized rat modelAnna Katri, Ditte Reker, Morten A Karsdal, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 20, 2020
Dose Frequency Optimization of the Dual Amylin and Calcitonin Receptor Agonist KBP-088: Long-Lasting Improvement in Food Preference and Body Weight LossAnna Thorsø Larsen, Nina Sonne, Kim V Andreassen, et al.
The Journal of Experimental Biology|July 10, 2015
Suppressed bone remodeling in black bears conserves energy and bone mass during hibernationMeghan McGee-Lawrence, Patricia Buckendahl, Caren Carpenter, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 26, 2017
The Dual Amylin- and Calcitonin-Receptor Agonist KBP-042 Works as Adjunct to Metformin on Fasting Hyperglycemia and HbA1c in a Rat Model of Type 2 DiabetesSara T Hjuler, Sofie Gydesen, Kim V Andreassen, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 30, 2020
The Dual Amylin and Calcitonin Receptor Agonist, KBP-066, Induces an Equally Potent Weight Loss Across a Broad Dose Range While Higher Doses May Further Improve Insulin ActionNina Sonne, Anna Thorsø Larsen, Kim Vietz Andreassen, et al.
Pageof 16

Showing results (31-40 of 154) with videos related to

Sort By:
Pageof 16
Scientific Reports|April 9, 2025
A fragment of Calpain-1 cleaved α-Synuclein quantified in serum is upregulated in patients with Parkinson's diseaseSigne Holm Nielsen, Cecilie Møller Hausgaard, Meryem Benmarce, et al.
European Journal of Clinical Pharmacology|October 9, 2009
Investigations of inter- and intraindividual relationships between exposure to oral salmon calcitonin and a surrogate marker of pharmacodynamic efficacyMorten A Karsdal, Inger Byrjalsen, Kim Henriksen, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|January 18, 2007
Are nonresorbing osteoclasts sources of bone anabolic activity?Morten A Karsdal, Thomas J Martin, Jens Bollerslev, et al.
BMC Endocrine Disorders|January 8, 2021
The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profileAnna Thorsø Larsen, Sofie Gydesen, Nina Sonne, et al.
European Journal of Pharmacology|June 2, 2015
KBP-042 improves bodyweight and glucose homeostasis with indices of increased insulin sensitivity irrespective of route of administrationSara T Hjuler, Kim V Andreassen, Sofie Gydesen, et al.
Menopause (New York, N.Y.)|January 5, 2021
Treatment with a dual amylin and calcitonin receptor agonist improves metabolic health in an old, obese, and ovariectomized rat modelAnna Katri, Ditte Reker, Morten A Karsdal, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 20, 2020
Dose Frequency Optimization of the Dual Amylin and Calcitonin Receptor Agonist KBP-088: Long-Lasting Improvement in Food Preference and Body Weight LossAnna Thorsø Larsen, Nina Sonne, Kim V Andreassen, et al.
The Journal of Experimental Biology|July 10, 2015
Suppressed bone remodeling in black bears conserves energy and bone mass during hibernationMeghan McGee-Lawrence, Patricia Buckendahl, Caren Carpenter, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 26, 2017
The Dual Amylin- and Calcitonin-Receptor Agonist KBP-042 Works as Adjunct to Metformin on Fasting Hyperglycemia and HbA1c in a Rat Model of Type 2 DiabetesSara T Hjuler, Sofie Gydesen, Kim V Andreassen, et al.
The Journal of Pharmacology and Experimental Therapeutics|January 30, 2020
The Dual Amylin and Calcitonin Receptor Agonist, KBP-066, Induces an Equally Potent Weight Loss Across a Broad Dose Range While Higher Doses May Further Improve Insulin ActionNina Sonne, Anna Thorsø Larsen, Kim Vietz Andreassen, et al.
Pageof 16